Cholesterol metabolism in patients with hemodialysis in the presence or absence of coronary artery disease

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 1980-1986

  Fukushima, Mikio ^a,b   Miura, Shin ichiro ^a   Mitsutake, Ryoko ^a   Fukushima, Takao ^b   Fukushima, Katsuhiko ^b   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Cholesterol; Coronary artery disease; Hemodialysis; Lipids

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CAMPESTEROL; CHOLESTANOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITOSTEROL; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GAS CHROMATOGRAPHY; GENDER; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INCIDENCE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE;

AGED; CHOLESTEROL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 84864395498     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1302     Document Type: Article

References (31)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3): S112-S119.
2. Kronenberg F. Lipoprotein abnormalities in end-stage renal failure. In: Loscalzo J, London GM, editors. Cardiovascular disease in endstage renal failure. Oxford: Oxford University Press, 2000; 175-206.
3. Bagdade JD, Porte D Jr, Bierman EL. Hypertriglyceridemia: A metabolic consequence of chronic renal failure. N Engl J Med 1968; 279: 181-185.
4. Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis, and transplantation. Kidney Int 1981; 19: 625-637.
5. Fuh MMT, Lee CM, Jeng CY, Shen DC, Shieh SM, Reaven GM, et al. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990; 37: 1295-1300.
6. Dieplinger H, Schoenfeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease: Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 1986; 77: 1071-1083.
7. Kronenberg F, KÖnig P, Neyer U, Auinger M, Pribasnig A, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-120.
8. Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis: Report of the Diaphane collaborative study. Nephron 1982; 31: 103-110.
9. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
10. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: A prospective study. J Am Coll Cardiol 2006; 48: 708-714.
11. Matthan NR, Pencina M, LaRocque JM, Jacques PF, D'Agostino RB, Schaefer EJ, et al. Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD. J Lipid Res 2009; 50: 1927-1935.
12. Chan DC, Watts GF, Barrett PH, O'Neill FH, Thompson GR. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Obes Res 2003; 11: 591-596.
13. Miettinen TA, Gylling H. Choletserol absorption efficiency and sterol metabolism in obesity. Atherosclerosis 2000; 153: 241-248.
14. Gylling H, Miettinen TA. Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diabetes Care 1997; 20: 90-95.
15. Lally S, Tan CY, Owens D, Tomkin GH. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: The role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein. Diabetologia 2006; 49: 1008-1016.
16. Sutherland WH, Walker RJ, Ball MJ, Stapley SA, Corboy J, Robertson MC. Cholesterol precursor concentration in plasma from patients with chronic renal failure or kidney grafts. Clin Nephrol 1995; 43: 392-398.
17. Igel-Korcagova A, Raab P, Brensing KA, Pöge U, Klehr HU, Igel M, et al. Cholesterol metabolism in patients with chronic renal failure on hemodialysis. J Nephrol 2003; 16: 850-854.
18. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557.
19. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353-359.
20. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
21. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
22. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
23. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-1500.
24. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508.
25. von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A, et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 2004; 110: 1579-1585.
26. Soeda T, Uemura S, Okayama S, Kawakami R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques: Evaluation using dual-source computed tomography. Circ J 2011; 75: 2621-2627.
27. Otagiri K, Tsutsui H, Kumazaki S, Miyashita Y, Aizawa K, Koshikawa M, et al. Early intervention with rosuvastatin decreases the lipid components of the plaque in acute coronary syndrome: Analysis using integrated backscatter IVUS (ELAN study). Circ J 2011; 75: 633-641.
28. Hirayama A, Saito S, Ueda Y, Takayama T, Honye J, Komatsu S, et al. Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound. Circ J 2011; 75: 1448-1454.
29. Strandberg TE, Tilvis RS, Pitkala KH, Miettinen TA. Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: A prospective study. J Am Coll Cardiol 2006; 48: 708-714.
30. Hattori S, Hattori Y. Efficacy and safety of ezetimibe in patients undergoing hemodialysis. Endocr J 2010; 57: 1001-1005.
31. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 2011; 377: 2181-2192.